The hantavirus outbreak on a cruise ship is causing new speculation about Moderna. Investors are once again betting on the potential of mRNA technology.
• Hantavirus outbreak drives interest in Moderna
• Analysts currently see hardly any direct sales opportunities
• ASCO oncology data remains the key price driver
The shares of the US biotech company Moderna are currently experiencing a renaissance on the financial markets, which is strongly reminiscent of the volatility during the pandemic years. As the business magazine Barron’s reports, the renewed investor interest is primarily due to an outbreak of the hantavirus on board the cruise ship MV Hondius. Although the company recently struggled with mixed quarterly results, news of the pathogen led to a massive increase in searches for Moderna vaccines and fueled speculation about a new phase of growth for the mRNA researcher, the report continued.
Medical relevance versus commercial potential
The Hantavirus, which can have a mortality rate of up to 50 percent, is considered highly dangerous, but experts say it is far less contagious than the coronavirus. Since the virus primarily occurs in certain regions of South America, Asia and Europe, analysts currently classify the sales opportunities as low. Experts at Evercore ISI emphasized to Barron’s that there is currently no “significant revenue opportunity” and that the stock tends to react to headlines about outbreaks that go far beyond the actual commercial impact. Still, Moderna confirmed it was in the early stages of researching treatments, part of a broader push against emerging infectious diseases.
Price rally and fundamental drivers on the NASDAQ
The market reaction to these developments is nevertheless enormous. The Moderna share, which already gained around 12 percent on the NASDAQ last Friday, continues its high at the start of the week and increased by a further 8.67 percent to $59.17 before the trading session. Since the beginning of the year, the paper has recorded an impressive increase of 84.30 percent. Despite the current Hantavirus euphoria, analysts such as Salveen Richter from Goldman Sachs point out, according to the report, that the actually decisive impulses for the share value can be expected at the end of May. Then, at the ASCO 2026 oncology conference, Moderna will present key five-year data on its mRNA-based cancer vaccine, which is being developed in collaboration with Merck.
Strategic partnerships and the future of mRNA technology
Regardless of the current outbreak, Moderna has been researching hantaviruses for years in collaboration with the US Army Medical Research Institute. Through the “mRNA Access” program, the company also makes its technology available to external partners to advance treatments against various pathogens. While developing a market-ready hantavirus agent could still take years, according to Barron’s, the oncology portfolio remains the real anchor for future evaluation. Analysts at Needham describe these programs as the group’s key future value drivers, which go far beyond the speculative interest in current waves of infections.
Between speculative virus fantasy and long-term oncology story
What remains crucial for investors is whether the current price rally proves to be a sustainable trend or just a short-term reaction to the hantavirus headlines. While analysts currently assess the direct sales opportunities associated with Hantavirus as low, Moderna’s oncology pipeline is increasingly becoming the focus of institutional investors. In particular, the upcoming data on the cancer vaccine developed jointly with Merck at ASCO 2026 is considered a potentially important valuation factor for the share. At the same time, the latest price development shows that Moderna continues to react strongly to news about infectious diseases and new mRNA applications on the stock market.
Claudia Stephan, editorial team at finanzen.net
This text is for informational purposes only and does not constitute an investment recommendation. finanzen.net GmbH excludes any claims for recourse.
By the way: Merck and other US stocks can even be traded on finanzen.net ZERO until 11 p.m. (without order fees, plus spreads). Open a depot now for free and secure a new customer bonus!
Selected leverage products on Merck
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Merck
The leverage must be between 2 and 20
Advertising
